UC Scientist Awarded $1.5 Million Grant to Study Breast Cancer

A UC scientist has received a five-year, $1.5 million National Cancer Institute grant to study the link between one of the body's naturally occurring "receptor" proteins and breast cancer.

Susan Waltz, PhD, associate professor in the Department of Surgery at the UC Medical Center, will investigate the function of the Ron receptor tyrosine kinase. This protein occurs normally in epithelial cells, which form the covering and lining of tissues in the body.

Receptors are specialized parts of a cell whose job is to respond to the chemical signals that control the function of the cell.  Specifically, the Ron receptor tyrosine kinase is believed to regulate cell division and migration.

Recently, Italian researchers noticed that a large fraction of breast tumors contained a significant over-production (20 fold) of the Ron receptor compared with normal breast tissue. This finding, and subsequent studies by Dr. Waltz's team, raised the possibility that over-production of the Ron receptor might actually be involved in the cause or progression of breast cancer.

 Although no one can yet explain the connection between increased Ron receptor protein and breast cancer, it does exist, and Dr. Waltz and her team have been able to reproduce this association in laboratory mice.

"It's a very promising direction," Dr. Waltz says, "and obviously a new target for investigation and therapy--so we jumped on it."

Tags

Related Stories

1

Certain weather patterns can trigger migraines

June 8, 2026

Certain weather patterns really do trigger migraine headaches — and the incidence is more common in the Midwest. As WGN 9 in Chicago recently reported, researchers at the University of Cincinnati College of Medicine have identified two specific weather patterns associated with an increased risk of headaches.

3

At least two weather patterns increase headaches, UC study suggests

June 4, 2026

University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.